Resveratrol enhances HBV replication through activating Sirt1-PGC-1α-PPARα pathway

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Shi, Yixian ^a   Li, Yongjun ^a   Huang, Chenjie ^a   Ying, Lixiong ^b   Xue, Jihua ^c   Wu, Haicong ^d   Chen, Zhi ^a   Yang, Zhenggang ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d FUZHOU GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; SIRTUIN 1; STILBENE DERIVATIVE;

ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; METABOLISM; MOUSE; PHYSIOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PPAR ALPHA; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; TRANSCRIPTIONAL ACTIVATION; VIRUS REPLICATION;

EID: 84964917260     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24744     Document Type: Article

References (54)

1. Dandri, M. & Locarnini, S. New insight in the pathobiology of hepatitis B virus infection. Gut 61 Suppl 1, 16-17, doi: 10.1136/ gutjnl-2012-302056 (2012).
2. Ford, E. S., Giles, W. H. & Dietz, W. H. Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey. Jama-J Am Med Assoc 287, 356-359, doi: DOI 10.1001/jama.287.3.356 (2002).
3. Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645, doi: 10.1161/CIRCULATIONAHA.109.192644 (2009).
4. Isomaa, B. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001).
5. Alberti, K. G., Zimmet, P., Shaw, J. & Group, I. D. F. E. T. F. C. The metabolic syndrome-a new worldwide definition. Lancet 366, 1059-1062, doi: 10.1016/S0140-6736(05)67402-8 (2005).
6. Kaur, J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014, 943162, doi: 10.1155/2014/943162 (2014).
7. Wong, V. W. et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 56, 533-540, doi: 10.1016/j. jhep.2011.09.013 (2012).
8. Jan, C. F. et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes 30, 794-799, doi: 10.1038/sj.ijo.0803204 (2006).
9. Li, W. C. et al. Association between the hepatitis B and C viruses and metabolic diseases in patients stratified by age. Liver Int 33, 1194-1202, doi: 10.1111/liv.12224 (2013).
10. Wong, G. L. et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 58, 111-117, doi: 10.1136/ gut.2008.157735 (2009).
11. Wong, G. L. et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 39, 883-893, doi: 10.1111/ apt.12658 (2014).
12. Wang, C. C., Tseng, T. C. & Kao, J. H. Hepatitis B virus infection and metabolic syndrome: fact or fiction? J Gastroenterol Hepatol 30, 14-20, doi: 10.1111/jgh.12700 (2015).
13. Chen, C. L. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135, 111-121, doi: 10.1053/j.gastro.2008.03.073 (2008).
14. Jeon, B. T. et al. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 61, 1444-1454, doi: 10.2337/db11-1498 (2012).
15. Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122, doi: 10.1016/j.cell.2006.11.013 (2006).
16. Marques, F. Z., Markus, M. A. & Morris, B. J. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41, 2125-2128, doi: 10.1016/j.biocel.2009.06.003 (2009).
17. Liu, T. et al. Resveratrol inhibits the TRIF-dependent pathway by upregulating sterile alpha and armadillo motif protein, contributing to anti-inflammatory effects after respiratory syncytial virus infection. J Virol 88, 4229-4236, doi: 10.1128/JVI.03637- 13 (2014).
18. Palamara, A. T. et al. Inhibition of influenza A virus replication by resveratrol. J Infect Dis 191, 1719-1729, doi: 10.1086/429694 (2005).
19. Li, Y. Q. et al. Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication. Eur J Med Chem 41, 1084-1089, doi: 10.1016/j.ejmech.2006.03.024 (2006).
20. Heredia, A., Davis, C. & Redfield, R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr (1999) 25, 246-255 (2000).
21. Docherty, J. J. et al. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 43, 145-155 (1999).
22. Docherty, J. J., Smith, J. S., Fu, M. M., Stoner, T. & Booth, T. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antiviral Res 61, 19-26 (2004).
23. Nakamura, M. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J Gastroenterol 16, 184, doi: 10.3748/wjg.v16.i2.184 (2010).
24. Yang, P. L., Althage, A., Chung, J. & Chisari, F. V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 99, 13825-13830, doi: 10.1073/pnas.202398599 (2002).
25. Tian, Y., Chen, W. L. & Ou, J. H. Effects of interferon-alpha/beta on HBV replication determined by viral load. PLoS Pathog 7, e1002159, doi: 10.1371/journal.ppat.1002159 (2011).
26. Bar-Yishay, I., Shaul, Y. & Shlomai, A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int 31, 282-290, doi: 10.1111/j.1478-3231.2010.02423.x (2011).
27. Ajmo, J. M., Liang, X., Rogers, C. Q., Pennock, B. & You, M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295, G833-842, doi: 10.1152/ajpgi.90358.2008 (2008).
28. Park, S. J. et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421-433, doi: 10.1016/j.cell.2012.01.017 (2012).
29. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342, doi: 10.1038/ nature05354 (2006).
30. Sun, C. et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 6, 307-319, doi: 10.1016/j.cmet.2007.08.014 (2007).
31. Hubbard, B. P. & Sinclair, D. A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 35, 146-154, doi: 10.1016/j.tips.2013.12.004 (2014).
32. Um, J. H. et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59, 554-563, doi: 10.2337/db09-0482 (2010).
33. Thornburg, J. M. et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 10, R84, doi: 10.1186/bcr2154 (2008).
34. Purushotham, A. et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9, 327-338, doi: 10.1016/j.cmet.2009.02.006 (2009).
35. Timmers, S. et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14, 612-622, doi: 10.1016/j.cmet.2011.10.002 (2011).
36. Chung, J. H., Manganiello, V. & Dyck, J. R. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol 22, 546-554, doi: 10.1016/j.tcb.2012.07.004 (2012).
37. Shlomai, A., Paran, N. & Shaul, Y. PGC-1alpha controls hepatitis B virus through nutritional signals. Proc Natl Acad Sci USA 103, 16003-16008, doi: 10.1073/pnas.0607837103 (2006).
38. Leone, T. C., Weinheimer, C. J. & Kelly, D. P. A critical role for the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the cellular fasting response: The PPAR alpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96, 7473-7478, doi: DOI 10.1073/pnas.96.13.7473 (1999)
39. Kersten, S. et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103, 1489-1498, doi: 10.1172/JCI6223 (1999).
40. Hung, L. M., Chen, J. K., Huang, S. S., Lee, R. S. & Su, M. J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47, 549-555 (2000).
41. de la Lastra, C. A. & Villegas, I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 49, 405-430, doi: 10.1002/mnfr.200500022 (2005).
42. Schneider, Y. et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158, 85-91 (2000).
43. Patel, K. R. et al. Clinical trials of resveratrol. Ann N Y Acad Sci 1215, 161-169, doi: 10.1111/j.1749-6632.2010.05853.x (2011).
44. Smoliga, J. M., Baur, J. A. & Hausenblas, H. A. Resveratrol and health-a comprehensive review of human clinical trials. Mol Nutr Food Res 55, 1129-1141, doi: 10.1002/mnfr.201100143 (2011).
45. Meng, X., Maliakal, P., Lu, H., Lee, M. J. & Yang, C. S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52, 935-942, doi: 10.1021/jf030582e (2004).
46. Gu, X., Creasy, L., Kester, A. & Zeece, M. Capillary electrophoretic determination of resveratrol in wines. J Agric Food Chem 47, 3223-3227 (1999).
47. Kaeberlein, M. et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280, 17038-17045, doi: 10.1074/jbc. M500655200 (2005).
48. Ren, J. H. et al. Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J Virol 88, 2442-2451, doi: 10.1128/JVI.02861-13 (2014).
49. Curtil, C. et al. The metabolic sensors FXRalpha, PGC-1alpha, and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J 28, 1454-1463, doi: 10.1096/fj.13-236372 (2014).
50. Kitada, M., Kume, S., Imaizumi, N. & Koya, D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60, 634-643, doi: 10.2337/db10- 0386 (2011).
51. Chen, L. L. et al. Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial beta-oxidation. Metabolism 60, 1598-1609, doi: 10.1016/j.metabol.2011.04.002 (2011).
52. Esposito, E. et al. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPARalpha. J Neuroinflammation 9, 81, doi: 10.1186/1742-2094-9-81 (2012).
53. Guidotti, L. G., Matzke, B., Schaller, H. & Chisari, F. V. High-level hepatitis B virus replication in transgenic mice. J Virol 69, 6158-6169 (1995).
54. Laras, A., Koskinas, J., Dimou, E., Kostamena, A. & Hadziyannis, S. J. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology (Baltimore, Md.) 44, 694-702, doi: 10.1002/hep.21299 (2006).